By September, the first H1N1 (swine) flu vaccines will be approved and ready for use, WHO director of the Initiative for Vaccine Research Marie-Paule Kieny said Thursday, Reuters reports.
The AP/San Francisco Chronicle examines Los Alamos National Laboratory researchers’ efforts to create an automated network to monitor animals in an effort to predict disease outbreaks because two out of every three human diseases “originated in animals.”
Efforts to fast-track the approval of H1N1 (swine) flu vaccines will not compromise the safety or quality controls of vaccine production, the WHO said in a written statement Thursday, the Mail & Guardian reports.
The WHO on Tuesday maintained that roughly two billion people could become infected with the H1N1 (swine flu) virus, Reuters reports.
The Agence-France Press examines the debate over how much developed countries are spending to fight the H1N1 virus.
“A U.S. plan to rely on swine flu vaccines without ingredients to stretch the supply [known as adjuvants] would reduce the number of available shots just when other countries need them most, the British journal Lancet said in an editorial,” Bloomberg writes.
During a meeting in Atlanta on Wednesday, a “federal advisory committee issued sweeping guidelines â€¦ for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations,” CNN reports (Hellerman, 7/29).
Health officials are growing increasingly concerned over the impact the H1N1 (swine) flu is having on populations living in Latin America, a region “which accounts for around two-thirds of the 816 confirmed deaths so far from the disease,” the AFP/channelnewsasia.com reports.
The WHO on Friday said the “H1N1 swine-flu virus could infect up to two billion people over the next two years – about one of every three people in the world,” VOA News reports.
“Global health officials are scrambling to try to prevent the spread of the H1N1 swine flu virus, with U.S. officials moving Thursday with a recommendation that the Food and Drug Administration approve or license a [new H1N1] vaccine,” without waiting on the results from “clinical trials to test its safety and efficacy,” Wall Street Journal reports (Dooren/Winning, 7/24).